Literature DB >> 16461990

Eosinophils and urticaria.

Delphine Staumont-Sallé1, David Dombrowicz, Monique Capron, Emmanuel Delaporte.   

Abstract

Previously believed to have an exclusive role in the release of cytotoxic mediators in the defense against helminthic infections, eosinophils are now considered key players in inflammatory reaction and regulation of immune response. Through activation of a large variety of membrane receptors and production of various pharmacologically active mediators, eosinophils may exert a detrimental role in tissues in which they have been recruited and may contribute to the perennization of inflammatory processes. The crucial role of eosinophils has been documented in several eosinophilic skin diseases, such as hypereosinophilic syndrome and bullous pemphigoid, and the literature provides strong evidence for their role in urticaria. The aim of this article is to discuss the mechanisms of specific tissue recruitment of eosinophils, the factors of eosinophil activation, and the contribution of these cells to inflammation and immunoregulation in urticaria. Recent advances in the knowledge of eosinophils will certainly help toward developing new strategies for the management of antihistamines resistant to urticaria.

Entities:  

Mesh:

Year:  2006        PMID: 16461990     DOI: 10.1385/CRIAI:30:1:013

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  32 in total

1.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.

Authors:  Sabine-Gisela Plötz; Hans-Uwe Simon; Ulf Darsow; Dagmar Simon; Ekatherina Vassina; Shida Yousefi; Rüdiger Hein; Tim Smith; Heidrun Behrendt; Johannes Ring
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

2.  Free eosinophil granules in urticaria: a correlation with the duration of wheals.

Authors:  M Toyoda; T Maruyama; M Morohashi; J Bhawan
Journal:  Am J Dermatopathol       Date:  1996-02       Impact factor: 1.533

Review 3.  The role of substance P in inflammatory disease.

Authors:  Terence M O'Connor; Joseph O'Connell; Darren I O'Brien; Triona Goode; Charles P Bredin; Fergus Shanahan
Journal:  J Cell Physiol       Date:  2004-11       Impact factor: 6.384

4.  Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.

Authors:  E Nettis; M C Colanardi; M T Paradiso; A Ferrannini
Journal:  Clin Exp Allergy       Date:  2004-09       Impact factor: 5.018

5.  Human eosinophils produce biologically active IL-12: implications for control of T cell responses.

Authors:  M Grewe; W Czech; A Morita; T Werfel; M Klammer; A Kapp; T Ruzicka; E Schöpf; J Krutmann
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

Review 6.  Late-phase urticaria Update.

Authors:  Naotomo Kambe; Aki Kitao; Chikako Nishigori; Yoshiki Miyachi
Journal:  Curr Allergy Asthma Rep       Date:  2002-07       Impact factor: 4.919

7.  Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2.

Authors:  H Hirai; K Tanaka; O Yoshie; K Ogawa; K Kenmotsu; Y Takamori; M Ichimasa; K Sugamura; M Nakamura; S Takano; K Nagata
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

8.  Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes.

Authors:  G Woerly; N Roger; S Loiseau; D Dombrowicz; A Capron; M Capron
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

9.  The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment.

Authors:  S Ying; L Taborda-Barata; Q Meng; M Humbert; A B Kay
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

10.  Activation of basophil and mast cell histamine release by eosinophil granule major basic protein.

Authors:  M C O'Donnell; S J Ackerman; G J Gleich; L L Thomas
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  8 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 3.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 4.  New insights on classification, identification, and clinical relevance of Blastocystis spp.

Authors:  Kevin S W Tan
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 5.  Pulmonary eosinophilia.

Authors:  Uriel Katz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

6.  Association of the blood eosinophil count with end-organ symptoms.

Authors:  Ole Weis Bjerrum; Volkert Siersma; Hans Carl Hasselbalch; Bent Lind; Christen Lykkegaard Andersen
Journal:  Ann Med Surg (Lond)       Date:  2019-07-09

7.  Localized and Generalized Skin Adverse Drug Reactions to Nadroparin Calcium Injection in 6 Cases of Pregnant Women.

Authors:  Ting Chen; Liling Lan; Wenwen Sun; Jia Yu; Baozhen Lu; Lijie Chen; Liwei Sun; Zhendong Yu; Bo Wu; Ying Xiong
Journal:  J Healthc Eng       Date:  2022-04-15       Impact factor: 3.822

8.  Serum Levels of Vascular Endothelial Growth Factor, Platelet Activating Factor and Eosinophil-Derived Neurotoxin in Chronic Spontaneous Urticaria-A Pilot Study in Adult Patients.

Authors:  Krzysztof Gomułka; Wojciech Mędrala
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.